SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has been featured in a BioMedWire editorial that examines the evolution of GLP-1 therapies and emerging innovation in the treatment of obesity and metabolic disease. The editorial highlights SureNano’s subsidiary GlucaPharm Inc. and its GEP-44 program, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in the rapidly expanding GLP-1 market.
The GLP-1 market has seen significant growth as demand continues for next-generation therapies targeting obesity, type 2 diabetes and related chronic conditions. GEP-44 is a patented peptide that addresses obesity and metabolic disorders with improved tolerability and potential non-injectable delivery, according to the company’s press release dated February 23, 2026. This innovation could offer patients more convenient treatment options and better outcomes.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with potential to address large and growing global health markets. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company, to bolster its pipeline. The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano™ surfactant, a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create homogeneous and stable products while maximizing bioavailability, clarity, and taste. The company has an exclusive license to distribute the SureNano™ surfactant within Canada; Oklahoma, USA; and Colorado, USA.
SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease. The editorial notes that the GEP-44 program represents a significant step forward in the evolution of GLP-1 therapies, potentially offering improved patient compliance and expanded treatment options.
The BioMedWire editorial is part of a broader effort to highlight key developments in the biotechnology and life sciences sectors. BioMedWire is a specialized communications platform under the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release solutions, social media distribution, and tailored corporate communications solutions. The platform is uniquely positioned to serve private and public companies seeking to reach investors, influencers, and the general public.
For more information on SureNano Science Ltd., the latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF. The full press release regarding this announcement can be viewed at https://ibn.fm/AGdi9.
The implications of this innovation are significant for the healthcare industry and patients. With obesity and metabolic diseases reaching epidemic proportions globally, next-generation therapies like GEP-44 could provide more effective and tolerable treatment options. The potential for non-injectable delivery may also improve patient adherence, addressing a major barrier in current GLP-1 therapies. As SureNano Science Ltd. advances its pharmaceutical focus, the company is positioned to play a key role in the evolving landscape of metabolic disease treatment.
